Skip to main content

Bionano Genomics, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

BNGO$1.16+0.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

PART I. FINANCIAL INFORMATION3
Item 1. Financial Statements3
Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 (Unaudited)3
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025 (Unaudited)4
Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2026 and 2025 (Unaudited)5
Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2026 and 2025 (Unaudited)6
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 (Unaudited)7
Notes to Condensed Consolidated Financial Statements (Unaudited)9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations24
Item 3. Quantitative and Qualitative Disclosures about Market Risk38
Item 4. Controls and Procedures38
PART II. OTHER INFORMATION39
Item 1. Legal Proceedings39
Item 1A. Risk Factors39
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds40
Item 3. Defaults Upon Senior Securities40
Item 4. Mine Safety Disclosures40
Item 5. Other Information40
Item 6. Exhibits41
SIGNATURES43
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.